Trial Profile
Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UC CIMZIA
- 10 Dec 2021 Status changed from active, no longer recruiting to completed.
- 01 Mar 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 01 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.